Bio-Path Hldgs Inc Stock Price, News & Analysis

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced a live conference call scheduled for August 13, 2021, at 8:30 a.m. ET. During this call, the company will report its financial results for Q2 ended June 30, 2021, and discuss its business overview. Bio-Path is focused on developing its DNAbilize^® antisense RNAi nanoparticle technology, with its lead candidate, prexigebersen, currently in Phase 2 studies for blood cancers. The company is also preparing for FDA consideration of prexigebersen-A for solid tumors and has ongoing studies for BP1002 in lymphoma.

Bio-Path Holdings (NASDAQ:BPTH) announced the granting of a new patent by the U.S. Patent and Trademark Office for BP1003, an innovative cancer treatment designed to inhibit STAT3 expression. This patent (U.S. Patent No. 11,041,153) reinforces the company's proprietary DNAbilize technology, aimed at enhancing drug delivery for difficult-to-treat cancers like pancreatic cancer and acute myeloid leukemia. The company aims to advance BP1003's development in pancreatic cancer next year.

Bio-Path Holdings (NASDAQ: BPTH) announced encouraging Q1 2021 financial results with a net loss of $2.4 million ($0.43 per share), an improvement from $3.3 million ($0.90 per share) in Q1 2020. The company successfully completed the safety run-in of Stage 2 in its Phase 2 clinical trial for prexigebersen in treating acute myeloid leukemia (AML). Additionally, Bio-Path raised $13 million in a public offering, significantly increasing cash reserves to $30.8 million. Recent data presentations at notable conferences have bolstered awareness of its DNAbilize platform for cancer treatment.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced a live conference call and audio webcast scheduled for May 14, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021, which ended on March 31, 2021, along with a business overview. The company's proprietary DNAbilize^® antisense RNAi nanoparticle technology is being utilized to develop targeted cancer drugs, including its lead candidate, prexigebersen, currently in Phase 2 trials for blood cancers. This event will be accessible via phone or on the company's website.

Bio-Path Holdings announced the publication of a peer-reviewed article in Biomedicines, discussing challenges in antisense oligonucleotide drug delivery and highlighting the advantages of prexigebersen (BP1001). The authors emphasized prexigebersen's potential to address delivery challenges due to its unique properties, including stability and non-toxicity. Currently, prexigebersen is in a Phase 2 study targeting blood cancers, while a modified version is being considered for Phase 1 studies in solid tumors. The breakthrough technology could significantly enhance cancer treatment.

Bio-Path Holdings (NASDAQ: BPTH) announced preclinical data on BP1002, a novel antisense therapy targeting Bcl-2, at the AACR Annual Meeting on April 12, 2021. The study highlighted its efficacy in overcoming venetoclax resistance in acute myeloid leukemia (AML) patients. CEO Peter Nielsen expressed optimism for filing a second Investigational New Drug (IND) application and initiating clinical studies. With median survival under 3 months for relapsed patients, BP1002 represents a critical advancement for treatment options in this vulnerable group.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced the successful completion of the safety run-in phase of Stage 2 in its Phase 2 clinical study for prexigebersen (BP1001), targeting acute myeloid leukemia (AML). Six evaluable patients received the triple combination therapy of prexigebersen, decitabine, and venetoclax, with a favorable safety profile and no dose-limiting toxicities. Notably, 83% of patients demonstrated clinical activity. The trial continues enrolling patients, aiming for significant efficacy data to petition the FDA for accelerated approval.

Bio-Path Holdings (NASDAQ: BPTH) announced a virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting from April 10-15 and May 17-21, 2021. Dr. Maria Gagliardi will present pre-clinical studies of BP1002 combined with decitabine, targeting venetoclax-resistant cancer cells.

Presentation Details:
Date: April 10, 2021
Time: 8:30 am ET
Session: Biological Therapeutic Agents
Abstract Number: 939
Title: Efficacy of BP1002 with decitabine in resistant cells.

Bio-Path Holdings (NASDAQ:BPTH) announced its financial results for 2020, reporting a net loss of $10.9 million, or $2.83 per share, compared to a loss of $8.6 million in 2019. Research and development expenses rose to $6.6 million from $4.6 million, reflecting increased clinical activity. The company raised $13 million through a public offering and secured a new U.S. patent for its DNAbilize® platform technology. Bio-Path commenced a Phase 1 trial for BP1002.